Published in Curr Opin HIV AIDS on March 01, 2009
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Pharmacological modulation of chemokine receptor function. Br J Pharmacol (2012) 1.41
Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions. Retrovirology (2013) 0.99
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol (2015) 0.91
CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses (2010) 0.91
Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations. J Virol (2014) 0.84
Natural anti-CCR5 antibodies in HIV-infection and -exposure. J Transl Med (2011) 0.79
siRNA-based topical microbicides targeting sexually transmitted infections. Curr Opin Mol Ther (2010) 0.79
Antibody epitopes on g protein-coupled receptors mapped with genetically encoded photoactivatable cross-linkers. Biochemistry (2014) 0.77
Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies. AIDS Res Hum Retroviruses (2015) 0.75
Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies. Front Immunol (2016) 0.75
The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIV. Viral Immunol (2013) 0.75
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science (2005) 17.00
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 10.27
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med (1996) 7.06
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med (1997) 5.18
Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell (1999) 4.97
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 4.83
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest (1994) 4.63
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother (2006) 4.14
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med (1997) 3.48
Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem (1999) 3.35
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol (2007) 3.31
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol (2006) 2.97
The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol (2002) 2.90
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res Hum Retroviruses (2000) 2.77
Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol (1997) 2.67
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis (2008) 2.54
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol (1998) 2.38
Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A (2001) 2.35
Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol (2001) 2.32
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol (1999) 2.23
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol (2005) 2.16
Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A (2000) 2.16
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology (2005) 2.13
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology (2006) 1.97
A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis (2008) 1.95
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol (2003) 1.86
Biology of CCR5 and its role in HIV infection and treatment. JAMA (2006) 1.84
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol (2008) 1.84
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol (2007) 1.77
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol (2005) 1.68
The second extracellular loop of CCR5 is the major determinant of ligand specificity. J Biol Chem (1997) 1.62
Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology (2006) 1.59
Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology (2008) 1.56
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol (2001) 1.55
Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell (2002) 1.39
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br J Clin Pharmacol (2008) 1.36
The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology (1998) 1.33
An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology (2006) 1.29
Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS (2007) 1.27
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother (2006) 1.23
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis (2008) 1.22
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis (2008) 1.22
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology (2007) 1.21
Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: implications for chemotaxis. J Cell Biol (1999) 1.20
HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci U S A (2000) 1.19
CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor. Mol Pharmacol (2007) 1.06
Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol (2003) 1.06
Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology (2008) 1.04
Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. Antimicrob Agents Chemother (2005) 1.01
Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Res (2006) 0.99
Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J Biol Chem (2000) 0.95
The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies. Antimicrob Agents Chemother (2007) 0.94
Resistance to HIV-1 entry inhibitors. Curr Drug Targets Infect Disord (2003) 0.83
Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail. J Clin Pharmacol (2006) 0.83
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140). J Allergy Clin Immunol (2006) 0.82
Directed selection of MIP-1 alpha neutralizing CCR5 antibodies from a phage display human antibody library. Nat Biotechnol (1998) 0.81
Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. Biochem Pharmacol (2007) 0.80
How pharmacological receptor theory can guide new drug discovery CCR5 HIV inhibitors in AIDS as a case study. Proc West Pharmacol Soc (2007) 0.76
Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med (2010) 6.26
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med (2013) 2.29
Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. J Immunol (2009) 1.52
Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses (2007) 1.46
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.39
Isolated levocardia: prenatal diagnosis, clinical importance, and literature review. J Ultrasound Med (2007) 1.34
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology (2006) 1.32
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis (2013) 1.26
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine (2009) 1.21
Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med (2013) 1.14
Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J Antimicrob Chemother (2010) 1.07
A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr (2006) 1.06
Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. PLoS Pathog (2013) 1.04
Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother (2011) 1.04
The critical need for alternative antiretroviral formulations, and obstacles to their development. J Infect Dis (2011) 1.04
Treatment interruption as a tool to measure changes in immunologic response to HIV-1. Curr Opin HIV AIDS (2008) 1.03
Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions. Retrovirology (2013) 0.99
Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 0.91
The prevalence of distress in persons with human immunodeficiency virus infection. Psychosomatics (2002) 0.91
New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists. Ther Clin Risk Manag (2008) 0.91
Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics (2003) 0.89
Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy. HIV Clin Trials (2011) 0.89
Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol (2011) 0.89
HIV- and AIDS-related knowledge, awareness, and practices in Madagascar. Am J Public Health (2003) 0.89
A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). J Acquir Immune Defic Syndr (2003) 0.89
CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr (2013) 0.89
Trials that matter: CD4+ T-lymphocyte count-guided interruption of antiretroviral therapy in HIV-infected patients. Ann Intern Med (2007) 0.87
Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes. Blood (2013) 0.86
Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS (2005) 0.86
Sedation during voiding cystourethrography: comparison of the efficacy and safety of using oral midazolam and continuous flow nitrous oxide. J Urol (2005) 0.85
IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. J Clin Invest (2016) 0.83
Cocaine alters cytokine profiles in HIV-1-infected African American individuals in the DrexelMed HIV/AIDS genetic analysis cohort. J Acquir Immune Defic Syndr (2014) 0.82
Mortality among HIV-Infected Patients in Resource Limited Settings: A Case Controlled Analysis of Inpatients at a Community Care Center. Am J Infect Dis (2009) 0.82
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. J Acquir Immune Defic Syndr (2013) 0.81
Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Hum Vaccin Immunother (2014) 0.79
Spirometry follow-up in young children with hemato-oncologic diseases. Med Sci Monit (2010) 0.79
Who should be reading chest radiographs in the pediatric emergency department? Pediatr Emerg Care (2012) 0.79
HIV-related pneumonia care in older patients hospitalized in the early HAART era. AIDS Patient Care STDS (2004) 0.78
The feasibility and validity of forced spirometry in ataxia telangiectasia. Pediatr Pulmonol (2010) 0.77
Actin integrity is indispensable for CD95/Fas-induced apoptosis of HIV-specific CD8+ T cells. Apoptosis (2007) 0.77
The yield of early postnatal ultrasound scan in neonates with documented antenatal hydronephrosis. Am J Perinatol (2011) 0.77
Effects of highly active antiretroviral therapy on HIV-1-associated oral complications. Curr HIV Res (2007) 0.77
Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van Lunzen. J Infect Dis (2013) 0.76
Ultra-fast low concentration detection of Candida pathogens utilizing high resolution micropore chips. Sensors (Basel) (2009) 0.75
A "buttressed mesh" technique for fascial closure in complex abdominal wall reconstruction. Ann Plast Surg (2009) 0.75
A reporting tool for real-time assessment of study data availability. Clin Trials (2004) 0.75
Type II single umbilical artery (persistent vitelline artery) in an otherwise normal fetus. Prenat Diagn (2002) 0.75
[Near fatal attraction of ingested magnets]. Harefuah (2013) 0.75